real-time news and commentary for investors
Thursday, Sep 20
2012, 9:46 AM
Biogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically...
Biogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically meaningful reductions" in relapses and brain lesions in patients with relapsing-remitting MS, data from two Phase III trials show. BG-12 also slowed the progress of the disease. The drug could be on track to become the third oral medicine for MS, as well as the safest and most effective. (PR)